We are a specialty biopharma company focused on innovating, reinventing, and optimising existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors.
We have built a broad proprietary pipeline of complex value-added reformulated and repurposed products that have the potential to offer significant advantages over currently available medications. Today, we have two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a novel, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain.
Our development strategy of reformulating and repurposing approved pharmaceuticals primarily utilises the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for which the safety and efficacy have already been established. This focused strategy can dramatically reduce the clinical burden required to bring a product to market, and significantly shortens the development timelines while also reducing costs and risks.
Hyloris is based in Liège, Belgium.
For more information, visit www.hyloris.com.
We have built a broad proprietary pipeline of complex value-added reformulated and repurposed products that have the potential to offer significant advantages over currently available medications. Today, we have two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a novel, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain.
Our development strategy of reformulating and repurposing approved pharmaceuticals primarily utilises the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for which the safety and efficacy have already been established. This focused strategy can dramatically reduce the clinical burden required to bring a product to market, and significantly shortens the development timelines while also reducing costs and risks.
Hyloris is based in Liège, Belgium.
For more information, visit www.hyloris.com.
Location: Belgium, Liège, Angleur
Employees: 11-50
Total raised: $16.42M
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | Nomainvest | nomainvest... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.04.2020 | - | $16.42M | - |
Mentions in press and media 7
| Date | Title | Description |
| 14.03.2024 | Hyloris Reports Full Year Results for 2023 & Provides Business Outlook | - |
| 08.03.2024 | Hyloris to Report 2023 Full-Year Results on 14 March 2024 | - |
| 08.06.2023 | Hyloris has been granted EUR 1 million in non-dilutive funding from the Walloon Region | - |
| 09.07.2022 | Pleco Therapeutics injected with €17.3 million to boost cancer treatment | Dutch clinical stage biopharmaceutical company Pleco Therapeutics has raised €17.3 million in funding to develop a portfolio of cancer therapies. The Series A round was backed by Oost NL, Hyloris Pharmaceuticals and Netherlands Enterprise A... |
| 01.04.2022 | Hyloris Successfully Raises EUR 15.0 Million in an Equity Offering by Means of A Private Placement Via an Accelerated Bookbuild Offering | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. PRESS RELEASE REGUL... |
| 17.12.2021 | Hyloris Enters into Strategic Partnership with Vaneltix for Treatment of Acute Pain in Interstitial Cystitis | Access to AlenuraTM, a dual mode-of-action advanced clinical candidate for the treatment of acute pain in interstitial cystitis/bladder pain syndrome (IC/BPS) Addressable patient population of at least 6 million1 in the U.S. Liège, Belgium ... |
| 30.04.2020 | Hyloris Pharmaceuticals Raises €15M in Funding | Hyloris Pharmaceuticals, a Liège, Belgium–based innovative specialty pharmaceutical company, raised €15m in funding. Backers included Scorpiaux, Noshaq, Saffelberg Investments and Nomainvest. Led by Stijn Van Rompay, Chief Executive Officer... |